Report Highlights
The global osteoarthritis therapeutics market should reach $11.2 billion by 2026 from $7.4 billion in 2021 at a compound annual growth rate (CAGR) of 8.6% for the forecast period of 2021 to 2026.
Report Includes
- 27 data tables and 33 additional tables
- An overview of the global market for osteoarthritis therapeutics
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for osteoarthritis therapeutics, based on type of anatomy, drug type, route of administration, purchasing pattern and region
- Discussion on recent developments of agents for the treatment of OA, which includes potential disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics for pain relief
- Description of pharmacological and non-pharmacological methods of OA management and information on personalized medicines for OA
- Discussion on the risk of adverse cardiovascular events related to the use of NSAIDs in osteoarthritis
- Coverage of clinical trials and applications of attractive drugs in preclinical research; regulatory scenarios, ongoing research on anti-NGF therapy and government expenditures
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast, and assessment of new developments in the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players, including Abbott Laboratories Inc., Bayer AG, Eli Lilly and Co., GlaxoSmithKline PLC, Pfizer Inc. and Sanofi.
Report Scope
This report provides a detailed description of the approaches used to treat pain management associated with osteoarthritis and the latest updates in the market. The report includes market estimates for different types of drugs and therapies used to treat osteoarthritis.
Based on anatomy, the osteoarthritis therapeutics market is segmented into knee osteoarthritis, hip osteoarthritis, others (shoulder, hand and small joint osteoarthritis).
Based on drug type, the osteoarthritis therapeutics market is segmented as viscosupplementation agents; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including ibuprofen, aspirin, diclofenac, naproxen, and other NSAIDs; analgesics; and corticosteroids.
Based on route of administration, the osteoarthritis therapeutics market is segmented into parenteral route, oral route and topical route.
Based on drug classification, the osteoarthritis therapeutics market is segmented into prescription drugs and over-the-counter (OTC) drugs.
The report discusses the qualitative and quantitative factors influencing market growth. Market drivers, restraints and opportunities are discussed in the report.
This report discusses some of the major drivers and restraints in the global osteoarthritis therapeutics market, as well as the competition and the key players’ strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors including company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for osteoarthritis therapeutics.
Some of the major market players discussed in the report are Sanofi S.A., Fidia Farmaceutici S.p.A, Seikagaku Corp., Anika Therapeutics Inc., Pfizer Inc. and GlaxoSmithKline PLC. For market estimates, data has been provided for 2020, which serves as the base year, with forecasts for 2021 through 2026. Estimated values used are based on manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2020 | ||||||||||||||||
| Forecast period considered | 2021-2026 | ||||||||||||||||
| Base year market size | $6.9 billion | ||||||||||||||||
| Market size forecast | $11.1 billion | ||||||||||||||||
| Growth rate | CAGR of 8.6% from 2021 to 2026 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Anatomy, Drug Type, Route of Administration, Classification | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||
| Countries covered | U.S., Canada, Germany, France, U.K., Spain, Italy, Rest of Europe, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Sweden, Japan, China, India, Australia, South Korea, Rest of Asia-Pacific, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Latin America, Middle East and North Africa, Sub-Saharan Africa | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Bioprocess Optimization and Digital Bio-manufacturing: Global Markets (BIO170B)
- Metal-organic Frameworks: Global Markets (AVM200B)
- Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets (PHM204C)
- Global DNA Sequencing: Research, Applied and Clinical Markets (BIO045J)
- Surgical Equipment: Technologies and Global Markets (HLC154C)
Related Reports
Viscosupplementation: Global Market Overview
The global viscosupplementation market should grow from $3.2 billion in 2018 to $5.9 billion by 2025 at compound annual growth rates (CAGR) of 9.0% for the period of 2018-2025.
Therapies for Rheumatoid Arthritis: Technologies and Global Markets
The global market for therapies for rheumatoid arthritis reached $19.0 billion in 2014. The market is expected to reach nearly $21.3 billion by 2020 from $19.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 1.3% from 2015 to 2020.
Recent Reports
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More